Blood Plasma Market to Reach USD 77,152.2 million by 2032, Growing at a CAGR of 10.4 % says Credence Research

Market Outlook

The blood plasma market size was valued at USD 34,962 million in 2024 and is anticipated to reach USD 77,152.2 million by 2032, at a CAGR of 10.4% during the forecast period (2024-2032). This strong growth trajectory is fueled by the increasing demand for plasma-derived therapies across various therapeutic applications, including immunology, hematology, and neurology. Plasma is a critical component in modern medicine, used in life-saving treatments for conditions such as immune deficiencies, hemophilia, and autoimmune diseases.

The market holds immense importance within the global healthcare system due to its role in producing therapeutic proteins, coagulation factors, and immunoglobulins. As chronic diseases and rare disorders continue to rise worldwide, the demand for plasma-derived products is expected to grow exponentially. Plasma therapies not only improve patient survival rates but also enhance quality of life, making them indispensable in both developed and emerging healthcare settings.

In the current global context, the relevance of the blood plasma market has intensified due to rising awareness of advanced treatment options, expanding access to healthcare, and continuous innovations in plasma fractionation. Additionally, governments and organizations are strengthening plasma collection systems to meet growing demand, while biopharmaceutical companies are investing heavily in research and development to expand the therapeutic scope of plasma-derived medicines. The market's expansion reflects not just medical necessity but also the evolving dynamics of healthcare innovation, regulation, and patient-centric treatment approaches.

Preview the report with a detailed sample and understand how it can benefit your business strategy. Request a free sample today https://www.credenceresearch.com/report/blood-plasma-market

Market Drivers

Rising Prevalence of Chronic and Rare Diseases
The increasing incidence of chronic illnesses and rare genetic disorders is a key driver of the blood plasma market. Conditions such as hemophilia, immune deficiencies, and autoimmune diseases necessitate long-term plasma-derived therapies, creating consistent demand. With an aging global population, the prevalence of such disorders continues to rise, thereby expanding the market scope. In addition, the growing awareness of plasma therapies among healthcare professionals and patients is reinforcing adoption. Governments are also taking initiatives to expand diagnosis and treatment coverage, which further boosts the utilization of plasma products. The rising patient population, coupled with improved disease management protocols, creates an ecosystem where demand for plasma-derived products remains steady and resilient. This trend ensures a sustained growth trajectory for the industry.

Growing Use of Immunoglobulins in Therapies
Immunoglobulins are among the most widely used plasma-derived products, addressing a range of conditions from immune deficiencies to neurological disorders. Recent advancements in therapeutic applications have expanded their usage, and the high efficacy of immunoglobulin treatments ensures steady demand across hospitals and specialty clinics. Increasing clinical evidence demonstrating the benefits of immunoglobulins in treating rare conditions is also strengthening their role in therapeutic regimens. Furthermore, ongoing innovation in delivery methods, such as subcutaneous options, has made these therapies more accessible and patient-friendly. Pharmaceutical companies are responding with expanded production capacities to meet surging demand, while clinical guidelines increasingly recommend immunoglobulins as standard care in multiple indications. This widespread acceptance highlights their importance as a cornerstone of plasma-based treatments.

Increasing Investments in Plasma Collection and Fractionation
Governments and private players are focusing on expanding plasma collection networks to address supply shortages. Advances in plasma fractionation technologies are also enhancing yield efficiency, ensuring better scalability. This infrastructure development not only boosts supply but also supports research into new plasma-derived products. Large pharmaceutical companies are investing in global plasma collection networks to strengthen self-sufficiency and reduce reliance on imports. New fractionation facilities are being commissioned across regions, especially in Asia Pacific and Europe, to meet regional demand more effectively. These investments are also leading to the diversification of product portfolios, allowing companies to explore next-generation plasma therapies. The push for innovation in both collection and processing reflects a long-term commitment to improving availability and affordability.

Expanding Applications in Emerging Markets
Emerging economies are experiencing rapid growth in healthcare infrastructure and awareness regarding plasma therapies. Rising disposable incomes, increasing health insurance penetration, and government healthcare programs are accelerating the adoption of plasma-derived treatments. This shift is enabling biopharma companies to tap into large patient populations previously underserved. Countries like India, China, and Brazil are witnessing rising demand due to higher diagnosis rates and better treatment accessibility. Local production initiatives and collaborations with global players are also supporting availability in these regions. Moreover, governments in developing markets are actively encouraging plasma donation and expanding national collection programs. As healthcare systems mature, these regions will become vital contributors to the overall market expansion, offering long-term growth potential.

Market Challenges

Supply Chain Limitations
The availability of plasma is highly dependent on donor participation, and fluctuations in supply can hinder consistent availability of therapies. This reliance creates bottlenecks in scaling production to meet rising demand. Seasonal variations, donor shortages, and logistical complexities further exacerbate the issue. Moreover, the increasing global demand often outpaces the rate of plasma collection, putting additional pressure on supply chains. While expansion of donation networks is underway, maintaining stable donor participation remains an ongoing challenge. Without adequate supply, even the most advanced plasma therapies cannot achieve their intended patient impact.

High Manufacturing and Processing Costs
Plasma fractionation is a complex and capital-intensive process requiring significant investments in technology and facilities. The high cost of production often translates to elevated therapy prices, limiting accessibility in lower-income regions. Additionally, strict quality standards and safety measures add further financial burdens for manufacturers. Companies are forced to balance affordability with innovation, which can slow product adoption in resource-constrained settings. Limited reimbursement options in several regions also restrict patient access. Addressing these cost challenges is essential to ensuring equitable global access to plasma therapies.

Stringent Regulatory Frameworks
Blood plasma products are subject to rigorous regulatory scrutiny due to their direct impact on patient health. Lengthy approval processes and strict quality control requirements can delay product launches and increase compliance costs for manufacturers. Regulatory bodies demand extensive clinical testing and validation before allowing commercialization. While these standards ensure patient safety, they also create barriers to rapid innovation. Smaller companies, in particular, face difficulties navigating complex approval systems. This regulatory intensity can slow the introduction of much-needed therapies to the market.

Competition from Alternative Therapies
Biotechnology advancements are introducing recombinant therapies and synthetic alternatives that can potentially replace plasma-derived products. These alternatives pose a long-term competitive challenge to the traditional plasma market. Recombinant factors in hemophilia care and synthetic immunoglobulins in development are examples of this trend. Patients and physicians may increasingly shift toward alternatives that promise greater consistency and scalability. While plasma therapies remain indispensable in many indications, continuous innovation from adjacent fields is reshaping competition. Companies must adapt by diversifying their pipelines and demonstrating the superior clinical outcomes of plasma-based products.

Market Opportunity

Growing Research in Rare Disease Treatments
Research advancements targeting rare diseases are unlocking opportunities for new plasma-derived therapies. Companies focusing on niche applications can secure competitive advantages in underserved segments. Rare disease treatments often attract government incentives and orphan drug designations, supporting faster approvals. Increasing collaboration with patient advocacy groups is also aiding research efforts in these specialized areas. As awareness and funding for rare disease management expand, plasma-based therapies will see wider acceptance. This creates a favorable environment for innovation-driven growth.

Expansion of Plasma Collection Centers Globally
The establishment of new plasma collection centers, particularly in developing regions, is expected to improve supply stability. This expansion can help meet growing patient demand worldwide. Governments are encouraging donations through awareness campaigns and incentives to build robust collection systems. International players are also entering new geographies to set up local operations, ensuring regional self-reliance. These efforts collectively strengthen the resilience of the supply chain. A broader donor base not only enhances production but also ensures cost stability in the long run.

Technological Innovations in Fractionation
Emerging technologies aimed at improving plasma fractionation efficiency are creating opportunities for higher yields and cost reductions. These innovations also support the development of novel therapies with improved patient outcomes. Automation and AI-driven quality control systems are increasingly being integrated into fractionation processes. Enhanced purification techniques are further expanding the scope of plasma-derived products. Companies investing in next-generation technologies can differentiate themselves in the competitive market. Technological progress will play a pivotal role in shaping the future of plasma therapies.

Strategic Collaborations and Partnerships
Collaborations between pharmaceutical companies, research institutes, and healthcare organizations are accelerating drug discovery and clinical trials. Such partnerships help diversify product pipelines while addressing unmet medical needs. Joint ventures also improve access to global markets, enabling companies to scale their operations. By combining expertise, partners can overcome R&D hurdles and shorten time-to-market for innovative therapies. These alliances foster a collaborative ecosystem that benefits both companies and patients. Strategic partnerships are likely to remain a key growth lever in the industry.

Market Segmentation

By Type:
• Immunoglobulins
• Albumin
• Coagulation Factors
• Protease Inhibitors
• Others

By Mode of Delivery:
• Intravenous
• Subcutaneous
• Intramuscular

By Therapeutic Indication:
• Primary Immunodeficiency
• Secondary Immunodeficiency
• Hemophilia
• Hereditary Angioedema
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Others

By Application:
• Therapeutics
• Diagnostics
• Research

By End User:
• Hospitals
• Clinics
• Blood Transfusion Centers
• Academic and Research Institutes

By Region:
• North America
o U.S.
o Canada
o Mexico

• Europe
o UK
o France
o Germany
o Italy
o Spain
o Russia
o Belgium
o Netherlands
o Austria
o Sweden
o Poland
o Denmark
o Switzerland
o Rest of Europe

• Asia Pacific
o China
o Japan
o South Korea
o India
o Thailand
o Indonesia
o Vietnam
o Malaysia
o Philippines
o Taiwan
o Rest of Asia Pacific

• Latin America
o Brazil
o Argentina
o Peru
o Chile
o Colombia
o Rest of Latin America

• Middle East & Africa
o GCC Countries
o South Africa
o Rest of the Middle East and Africa

Regional Analysis

North America
North America dominates the blood plasma market due to advanced healthcare infrastructure and strong investments in plasma collection. The U.S. leads with a robust network of donation centers and high consumption of plasma-derived therapies. Canada also contributes with structured regulatory frameworks that support safe collection and distribution. Ongoing investments in R&D further strengthen the region's leadership position. The high prevalence of chronic disorders ensures steady demand, while public-private partnerships enhance innovation. Collectively, these factors cement North America as the global hub of plasma therapies.

Europe
Europe represents a significant market share with countries like Germany, France, and the UK contributing substantially. Stringent regulations ensure product quality, while public health initiatives increase awareness about plasma therapies. The European Union actively promotes plasma donation programs to maintain self-sufficiency. Advances in healthcare policies also support broader access to therapies across member states. Leading pharmaceutical companies are headquartered here, driving innovation and clinical research. Europe's strong regulatory foundation positions it as a stable and reliable plasma market.

Asia Pacific
Asia Pacific is emerging as the fastest-growing region, fueled by rising healthcare expenditure, growing prevalence of chronic diseases, and increasing government support. China and India are leading with expanding plasma collection systems. Japan and South Korea also play vital roles with high adoption rates of advanced therapies. Increasing medical tourism in countries like Thailand adds another dimension to regional demand. Favorable government initiatives and healthcare reforms further accelerate growth. Asia Pacific's vast patient base offers unparalleled opportunities for long-term expansion.

Latin America
Latin America shows moderate growth, with Brazil and Argentina at the forefront. Improving healthcare infrastructure and government-backed programs are enhancing access to plasma therapies in the region. Efforts to raise awareness of plasma donation are slowly strengthening collection networks. International companies are collaborating with local partners to improve distribution. While economic disparities limit widespread adoption, steady progress is visible. The region's gradual shift toward advanced treatments highlights its untapped potential.

Middle East & Africa
The Middle East & Africa market is gradually expanding with increasing investments in healthcare systems. GCC countries and South Africa are emerging as key players, although access remains limited in some areas. Governments are launching initiatives to improve local plasma collection and encourage donations. Rising healthcare spending is also supporting the introduction of advanced therapies. While challenges such as infrastructure gaps persist, international partnerships are improving access. The region holds promise for future growth as systems become more developed.

Top Companies

• Allergan
• AbbVie Inc.
• GALDERMA
• Pfizer Inc.
• GlaxoSmithKline plc
• Merz Pharma (Germany)
• LGM Pharma
• Lannett
• NorthStar Rx LLC
• Medytox

Recent Developments

• In June 2023, Lannett successfully emerged from Chapter 11 bankruptcy, restructuring its debt and initiating a new growth phase centered on biosimilar insulin product development.

• In April 2024, NorthStar entered into a clinical supply agreement with Clarity to provide Cu-67 SAR-bisPSMA for pivotal clinical trials.

• In July 2024, Flagship Pioneering announced a partnership to develop up to 10 new drugs and vaccines, primarily targeting respiratory and immunology indications, with a projected value exceeding USD 7 billion.

Reasons to Purchase this Report:

• Gain in-depth insights into the market through both qualitative and quantitative analyses, incorporating economic and non-economic factors, with detailed segmentation and sub-segmentation by market value (USD Billion).

• Identify the fastest-growing regions and leading segments through analysis of geographic consumption trends and the key drivers or restraints affecting each market.

• Track the competitive landscape with updated rankings, recent product launches, strategic partnerships, business expansions, and acquisitions over the past five years.

• Access comprehensive profiles of key players, featuring company overviews, strategic insights, product benchmarking, and SWOT analyses to assess market positioning and competitive advantages.

• Explore current and projected market trends, including growth opportunities, key drivers, challenges, and limitations across developed and emerging economies.

• Leverage Porter's Five Forces analysis and Value Chain insights to evaluate competitive dynamics and market structure.

• Understand how the market is evolving and uncover future growth opportunities and emerging trends shaping the industry.

Related Reports -

Artificial Intelligence in Precision Medicine Market - https://www.credenceresearch.com/report/artificial-intelligence-in-precision-medicine-market

Virus Safety Testing Services Market - https://www.credenceresearch.com/report/virus-safety-testing-services-market

Follow Us:

https://www.linkedin.com/company/credenceresearch/

https://www.facebook.com/CredenceResearch

Credence Research Europe LTD - 128 City Road, London, EC1V 2NX, UNITED KINGDOM

Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives.

This release was published on openPR.